{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:42:26Z","timestamp":1792075346456,"version":"4.4.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjpo"],"accepted":{"date-parts":[[2025,2,23]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As a first-line therapeutic option for multisystem inflammatory syndrome in children (MIS-C) with surging demand, intravenous immunoglobulin (IVIG) is associated with escalating costs and supply shortages, particularly in low-income and middle-income countries. This study compares the effectiveness of methylprednisolone alone versus IVIG combined with methylprednisolone for managing MIS-C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study from January 2022 to June 2023 at Vietnam National Children\u2019s Hospital. We used propensity score matching to compare the short-term outcomes based on immunomodulatory therapy with methylprednisolone alone or IVIG plus methylprednisolone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 391 patients, comprising 255 boys and 136 girls, who fulfilled the MIS-C case definition of the US Centers for Disease Control and Prevention. Most patients (80.8%) received intravenous methylprednisolone monotherapy, and 19.2% were administered IVIG in addition to methylprednisolone. In general, the laboratory values indicative of hyperinflammatory and hyperthrombotic states displayed significant early response within 2\u20133\u2009days after initial treatment, including white cell count (SE=1.77, p&lt;0.001), NEU (SE=0.76, p=0.03), C reactive protein (SE=\u221246.51, p&lt;0.001), PLT (SE=38.05, p=0.002), fibrinogen (SE=\u22120.37, p=0.002), d-dimer (SE=\u2212849.8, p=0.02)); while subsequent improvement in cardiac markers was also observed, with pro-B-type natriuretic peptide (SE=\u2212165.2, p&lt;0.001) on day 5 and troponin I (SE=\u22120.05, p=0.004) on day 7. After propensity score weighting, there were 41 patients in each treatment group. Notably, there were no significant differences in the incidence of cardiac events between treatment groups regarding left ventricular dysfunction and coronary artery dilation or aneurysms (10.3% vs 20.7%, p=0.074\u2009and 63.4% vs 56.1%, p=0.653, respectively). While the median paediatric intensive care unit length of stay (LOS) and hospital LOS were slightly lengthier in the IVIG and methylprednisolone group compared with those of the methylprednisolone group, these differences were not statistically significant ((5 vs 4, p=0.782) and (9 vs 7, p=0.725), respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial treatment with methylprednisolone monotherapy appears not inferior in effectiveness to adjunctive IVIG plus methylprednisolone in MIS-C. Further investigations in randomised controlled trials deserve to be undergone to clarify if IVIG-sparing glucocorticoids are a viable option for achieving favourable outcomes in MIS-C, particularly in resource-limited settings with barriers approaching IVIG therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjpo-2024-003148","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T18:30:45Z","timestamp":1741199445000},"page":"e003148","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of methylprednisolone alone versus intravenous immunoglobulin plus methylprednisolone for multisystem inflammatory syndrome in children (MIS-C)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-446X","authenticated-orcid":false,"given":"Phuc Huu","family":"Phan","sequence":"first","affiliation":[{"name":"Pediatric Intensive Care Unit, Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canh Ngoc","family":"Hoang","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Thu T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Immunology, Allergy, and Rheumatology, Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung Viet","family":"Cao","sequence":"additional","affiliation":[{"name":"Heart Center, Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Quynh","family":"Le","sequence":"additional","affiliation":[{"name":"Immunology, Allergy, and Rheumatology, Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dien Minh","family":"Tran","sequence":"additional","affiliation":[{"name":"Vietnam National Children\u2019s Hospital, Ha Noi, Viet Nam"},{"name":"Faculty of Medicine and Pharmacy, Vietnam National University, Hanoi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2026010702004436000_9.1.e003148.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01051-8"},{"key":"2026010702004436000_9.1.e003148.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30304-7"},{"key":"2026010702004436000_9.1.e003148.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00709-9"},{"key":"2026010702004436000_9.1.e003148.4","doi-asserted-by":"crossref","first-page":"680813","DOI":"10.3389\/fped.2021.680813","article-title":"Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum","volume":"9","author":"Matucci-Cerinic","year":"2021","journal-title":"Front Pediatr"},{"key":"2026010702004436000_9.1.e003148.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40124-021-00259-4","article-title":"Treatment of MIS-C in Children and Adolescents","volume":"10","author":"Mahmoud","year":"2022","journal-title":"Curr Pediatr Rep"},{"key":"2026010702004436000_9.1.e003148.6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/art.42062","article-title":"American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3","volume":"74","author":"Henderson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026010702004436000_9.1.e003148.7","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s10067-022-06350-5","article-title":"Multisystem inflammatory syndrome in children: clinical presentation, management, and short- and long-term outcomes","volume":"41","author":"Sezer","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026010702004436000_9.1.e003148.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299"},{"key":"2026010702004436000_9.1.e003148.9","first-page":"2398","article-title":"Incidence and Risk Factors for IVIG-Mediated Hemolysis","volume":"130","author":"Pendergrast","year":"2017","journal-title":"Blood"},{"key":"2026010702004436000_9.1.e003148.10","article-title":"Corticosteroids for the treatment of Kawasaki disease in children","volume":"5","author":"Green","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010702004436000_9.1.e003148.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224123"},{"key":"2026010702004436000_9.1.e003148.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-278127"},{"key":"2026010702004436000_9.1.e003148.13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-061297","article-title":"Early Treatment of Multisystem Inflammatory Syndrome in Children","volume":"152","author":"Jonat","year":"2023","journal-title":"Pediatrics"},{"key":"2026010702004436000_9.1.e003148.14","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000600"},{"key":"2026010702004436000_9.1.e003148.15","first-page":"244","article-title":"Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison","volume":"104","author":"Darby","year":"2021","journal-title":"Am Fam Physician"},{"key":"2026010702004436000_9.1.e003148.16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamapediatrics.2022.0292","article-title":"Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children","volume":"176","author":"Villacis-Nunez","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2026010702004436000_9.1.e003148.17","unstructured":"CSTE\/cdc multisystem inflammatory syndrome in children (mis-c) associated with sars-cov-2 infection surveillance interim case reporting guide. 2022. Available: https:\/\/stacks.cdc.gov\/view\/cdc\/122831 [Accessed 14 Feb 2025]."},{"key":"2026010702004436000_9.1.e003148.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000484"},{"key":"2026010702004436000_9.1.e003148.19","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.12998\/wjcc.v10.i29.10435","article-title":"Age-adjusted NT-proBNP could help in the early identification and follow-up of children at risk for severe multisystem inflammatory syndrome associated with COVID-19 (MIS-C)","volume":"10","author":"Rodriguez-Gonzalez","year":"2022","journal-title":"World J Clin Cases"},{"key":"2026010702004436000_9.1.e003148.20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.cjco.2021.02.012","article-title":"Detailed Assessment of Left Ventricular Function in Multisystem Inflammatory Syndrome in Children, Using Strain Analysis","volume":"3","author":"Kobayashi","year":"2021","journal-title":"CJC Open"},{"key":"2026010702004436000_9.1.e003148.21","doi-asserted-by":"crossref","first-page":"15810","DOI":"10.1038\/s41598-024-66891-4","article-title":"Severity predictors for multisystemic inflammatory syndrome in children after SARS-CoV-2 infection in Vietnam","volume":"14","author":"Tran","year":"2024","journal-title":"Sci Rep"},{"key":"2026010702004436000_9.1.e003148.22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"Riphagen","year":"2020","journal-title":"The Lancet"},{"key":"2026010702004436000_9.1.e003148.23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.hrtlng.2022.03.007","article-title":"The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: A systematic review","volume":"54","author":"Kunal","year":"2022","journal-title":"Heart Lung"},{"key":"2026010702004436000_9.1.e003148.24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.rdc.2023.03.002","article-title":"Kawasaki Disease and Multisystem Inflammatory Syndrome in Children","volume":"49","author":"Noval Rivas","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"2026010702004436000_9.1.e003148.25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2352-4642(23)00316-4","article-title":"Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial","volume":"8","author":"Faust","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026010702004436000_9.1.e003148.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"2026010702004436000_9.1.e003148.27","doi-asserted-by":"crossref","unstructured":"Nocentini G , Migliorati G , Riccardi C . The molecular and cellular mechanisms responsible for the anti-inflammatory and immunosuppressive effects of glucocorticoids. In: Cimaz R , ed. Systemic corticosteroids for inflammatory disorders in pediatrics. Adis, Cham, 2015. Available: https:\/\/doi.org\/10.1007\/978-3-319-16056-6_4","DOI":"10.1007\/978-3-319-16056-6_4"},{"key":"2026010702004436000_9.1.e003148.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(03)00035-1"},{"key":"2026010702004436000_9.1.e003148.29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9088-9"},{"key":"2026010702004436000_9.1.e003148.30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jama.2021.0694","article-title":"Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children","volume":"325","author":"Ouldali","year":"2021","journal-title":"JAMA"},{"key":"2026010702004436000_9.1.e003148.31","doi-asserted-by":"publisher","DOI":"10.1161\/circulation.aha.120.050147"},{"key":"2026010702004436000_9.1.e003148.32","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9458653","article-title":"IVIG plus Glucocorticoids versus IVIG Alone in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Systematic Review and Meta-Analysis","volume":"2022","author":"Rauniyar","year":"2022","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2026010702004436000_9.1.e003148.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102968"},{"key":"2026010702004436000_9.1.e003148.34","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/S2665-9913(23)00029-2","article-title":"Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study","volume":"5","author":"Channon-Wells","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026010702004436000_9.1.e003148.35","article-title":"Clinical Efficacy of Intravenous Immunoglobulins in Management of Toxic Shock Syndrome: An Updated Literature Review","volume":"13","author":"Amreen","year":"2021","journal-title":"Cureus"},{"key":"2026010702004436000_9.1.e003148.36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1186\/s13063-021-05807-3","article-title":"Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial","volume":"22","author":"Lin","year":"2021","journal-title":"Trials"},{"key":"2026010702004436000_9.1.e003148.37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/1756-185X.12082","article-title":"Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients","volume":"16","author":"Sato","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"2026010702004436000_9.1.e003148.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.03.014"},{"key":"2026010702004436000_9.1.e003148.39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12969-020-00461-6","article-title":"Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease","volume":"18","author":"Inoue","year":"2020","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["BMJ Paediatrics Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjpo-2024-003148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:01:07Z","timestamp":1767780067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpaedsopen.bmj.com\/lookup\/doi\/10.1136\/bmjpo-2024-003148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,5]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjpo-2024-003148"],"URL":"https:\/\/doi.org\/10.1136\/bmjpo-2024-003148","relation":{},"ISSN":["2399-9772"],"issn-type":[{"value":"2399-9772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}